New hope for pancreatic cancer patients with specific mutation
NCT ID NCT07438106
Summary
This study is testing whether adding an experimental drug called HRS-4642 to standard chemotherapy can help shrink tumors in people with locally advanced pancreatic cancer that has a specific genetic mutation (KRAS G12D). The goal is to see if this combination makes tumors shrink enough to potentially allow for surgery. Researchers will monitor 30 participants for tumor response, safety, and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC CANCER WITH KRAS G12D MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Province Hospital
RECRUITINGNanjing, China
Contact
Conditions
Explore the condition pages connected to this study.